Regular Article
Adenomyosis in Postmenopausal Breast Cancer Patients Treated with Tamoxifen: A New Entity?

https://doi.org/10.1006/gyno.1995.1188Get rights and content

Abstract

Between September 1, 1989 and October 31, 1994, 173 post-menopausal breast cancer women on tamoxifen treatment were followed up in the authors' institutions. During this period, 14 (8.1%) underwent total abdominal hysterectomy and bilateral salpingo-oophorectomy for various indications. Eight (57.1%) were found to have adenomyosis, of whom one had a large fundal adenomyotic lump and the other seven patients had two to four small microscopic fact of adenomyosis. In this study, the rate of adenomyosis described among those postmenopausal breast cancer patients treated with tamoxifen is nearly three to four times higher than the rate reported in the literature for pre- and postmenopausal women. There is no previous reported increased incidence of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen. Thus, it is suggested that the prolonged and unopposed estrogen-like stimulation by tamoxifen may play a causal role rather than be a casual factor in the development of this pathologic entity.

References (0)

Cited by (65)

  • Adenomyosis: A Clinical Review of a Challenging Gynecologic Condition

    2016, Journal of Minimally Invasive Gynecology
    Citation Excerpt :

    Additionally, studies have shown increased rates of adenomyosis in patients who have received tamoxifen treatment. Tamoxifen binds to selective estrogen receptors and can stimulate both normal and ectopic endometrial tissue, fostering the development of adenomyosis [16,17,20]. Parity may be a risk factor because studies have shown an increased frequency of adenomyosis in multiparous patients [15].

  • Adenomyosis: A life-cycle approach

    2015, Reproductive BioMedicine Online
    Citation Excerpt :

    Tamoxifen use has been linked to postmenopausal adenomyosis and to an endometrioma in one case report (Le Bouëdec et al., 1991), and to adenomyosis and an adenomyomatous endometrial polyp in another (Ugwumadu et al., 1993); in a study (n = 8) of endometrial pathology during tamoxifen therapy, one had adenomyosis (Krause and Gerber, 1994). Cohen et al. (1995) reported adenomyosis in eight (57.1%) out of 14 women who had a hysterectomy while receiving tamoxifen. Seven had small microscopic foci, and one case was a large fundal adenomyotic lump.

  • Estradiol and tamoxifen enhance invasion of endometrial stromal cells in a three-dimensional coculture model of adenomyosis

    2014, Fertility and Sterility
    Citation Excerpt :

    Importantly, the invasive properties of stromal cells and the effect of myocytes retained their relation to the tissue of origin. Previous research suggested a role for estrogen in the pathogenesis of adenomyosis and also linked adenomyosis to tamoxifen use in women with breast cancer (15). The CD1 neonatal model showed a role for tamoxifen but not estradiol in the pathogenesis of adenomyosis (6).

  • Adenomyosis: Review of the Literature

    2011, Journal of Minimally Invasive Gynecology
  • Dysfunctional uterine bleeding: Diagnostic approach and therapeutic options

    2010, Ultrasound Clinics
    Citation Excerpt :

    Further, there has been no correlation between polyp size or malignancy and duration of treatment.45,46 Postmenopausal women taking tamoxifen have an increased risk of development of leiomyomas and adenomyosis.38,47 Tamoxifen therapy is associated with a statistically significantly increased risk of invasive endometrial cancer in women aged 50 years or older.

View all citing articles on Scopus
View full text